The Pediatric Early Phase-Clinical Trials Network (PEP-CTN) grant, supporting 21 premier Children’s Oncology Group (COG) pediatric core member sites in the U.S. and 21 non-core member sites in the U.S., Canada and Australia charged with early phase clinical trials, is primarily funded by the National Cancer Institute (NCI) and also receives additional funding from other granting agencies and from philanthropic sources (http://thecogfoundation.org).
Reviewer Comments- Competitive Application COG Pediatric Early Phase-Clinical Trial Network (PEP-CTN) Grant:
"The collective track record of successfully developing and delivering early phase trials is impressive as is the engagement with COG tumor groups to ensure a line of sight for the agents developed into subsequent disease specific late phase trials. All proposed Leaders are experts in their field that have a clear commitment to treating childhood cancers, a strength is the diversity across the whole proposed network. Leveraging the integrated relationship of the network has the potential to rapidly translate early promising results of trials of new anti-cancer agents in children to broader populations for evaluation in combination with current standard of care to improve current treatment outcomes. Also, integration of new agent prioritization with strategic planning for therapeutic studies in individual disease areas will inform both short-term and long-term clinical trial planning and conduct."